 |
|
|
| |
A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos(t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B - Interim results of the OCTOPUS-1 study
|
| |
| |
EASL 2024
Tarik Asselah1, Scott K. Fung2, Sila Akhan3, Wan-Long Chuang4, Maria Buti5, Maurizia Brunetto6, Kosh Agarwal7, Camellia Diba8,
John Jezorwski9, Thomas Kakuda10, Catherine Nalpas11, Carine Guinard-Azadian11, Thierry Verbinnen8, Erkki Lathouwers8,
An De Creus8, Oliver Lenz8, Michael Biermer8
1Université de Paris-Cité, INSERM UMR1149, Department of Hepatology, AP-HP Hôpital Beaujon, Clichy, France, 2Toronto General Hospital, Toronto Center for Liver Disease, Toronto, Canada, 3Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey, 4Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan, 5Hospital General Universitari Vall d'Hebron , Barcelona, Spain, 6Dept of Clinical and Experimental Medicine and Hepatology Unit, University of Pisa, Pisa, Italy, 7Insitute of Liver Studies, King's College Hospital, London, United Kingdom, 8Janssen Research & Development, Beerse, Belgium, 9Janssen Research & Development, Trenton, United States, 10Janssen Research & Development, South San Francisco, United States, 11Janssen Research & Development, Issy-les-Moulineaux, France
|
| |
|
|
|
|
|
